Revance Therapeutics Inc (RVNC)

[iwfal]

The subject (under-dosing, especially frontalis) came up briefly on the Blair webcast two days ago.

Perhaps I missed it (was doing chores at time), but all I heard was a 1 or 2 sentence description of using this startup period to feed results from early adopters into training for later adopters. ? Nothing specific to frontalis, which is, as best I can tell, the biggest/most-cared-about-by-users(?) uncertainty.